- 點擊【立即啟動】(藍框處)打開 Microsoft Edge
The National Agency of Drug and Food Control(Badan Pengawas Obat dan Makanan; BPOM) has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon
Oneness Biotech Co., Ltd. receives the United States patent on the producing recombinant glycoproteins with modified glycosylation.
Oneness submitted an IND to US FDA for a phase II clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai)
Announced The Board of Directors' resolution of 2023 that the related matters of ex-rights and ex-dividend.
Oneness announces on behalf of Cotton Field Organic Farm Inc., a major subsidiary, for shareholders’ meeting important resolutions of the 2023
The Company's 2023Q1 consolidated financial statements have been approved by the Board of Directors
Oneness Attends the 9th International Symposium on Diabetic Foot 2023 (ISDF2023)
The Phase 3 MRCT post-hoc analysis and the post-market hard-to-heal cases of the DFU new drug, Fespixon have been accepted for an oral presentation at EWMA 2023.
Oneness Biotech Co., Ltd. receives a Singaporean patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
Oneness was notified today that Bonvadis Cream for scar management has been granted import license in Europe.
Oneness announce the important resolutions of the 2023 Annual General Shareholders' Meeting
Announce the change of the corporate governance officer.
The board of directors of the Company approved removal of the noncompete clause for managers.
Oneness announces the information about the investor's conference of 2023 Q1.
Oneness received Medical Devices Export License approvals by TFDA on Bonvadis Topical Cream and Bonvadis Cream. The certificate will be collected accordingly.